Karen Sinclair talks synthetic biology on the From Idea to Intellectual Property podcast
Karen Sinclair joins host Lisa Leong on the From Idea to Intellectual Property podcast series to discuss the emerging trends and key issues in the area of synthetic biology.
Reversal of fortune – Full Court decides that an artificial intelligence is not an “inventor”
Anthony Selleck reviews the decision in Commissioner of Patents v Thaler  FCAFC 62 which reverses an earlier ruling that artificial intelligence can be an “inventor” for the purposes of the Australian Patents Act 1990.
Griffith Hack announces the promotion of five team members
Griffith Hack is proud to announce the promotion of five members of our team, including the elevation of Jennifer Wyndham-Wheeler to principal.
Spotlight Series: Regenerative Medicine – Part 2
Welcome to the second article of our Spotlight Series on one of the most exciting frontiers of scientific research and innovation, regenerative medicine.
Amanda Stark, Janelle Borham named Patent Stars for 2022 by Managing IP
Griffith Hack principals Amanda Stark and Janelle Borham have been named as Patent Stars in the IP STARS 2022 rankings by Managing IP.
AI and Digital Capability Centre Grants: What you need to know before applying
Applications are now open for Artificial Intelligence (AI) and Digital Capability Centre Grants of up to $11 million. Here’s what you need to know before applying.
Federal Budget 2022: What’s in it to accelerate Australia’s innovation agenda?
We discuss the key measures in Australia’s 2022-23 federal budget that could help drive innovation, research commercialisation and business growth.
From idea to inception and beyond: Important learnings from female biotech founders
Female biotech founders took centre-stage at AusBiotech 2021 with the leaders of some of Australia’s most innovative start-ups coming together to discuss their experiences in the commercial scientific world.
Saving grace: Options if you disclose your invention without a patent application
Publicly disclosing new technology before a patent application has been filed can jeopardise patent coverage – but there are options available to you in the event of disclosure.
Virus filtration patent gets clean bill of health
In a recent decision of the Australian Patent Office, a patent application directed to a membrane for filtering biological products was upheld following opposition.
Jacqui Thomas, Daniel Hsieh register as patent attorneys in Australia and New Zealand
Griffith Hack is pleased to announce that Jacqui Thomas and Daniel Hsieh are now registered patent attorneys in Australia and New Zealand.
Awkward first dates:
How is patent term extension calculated when a patent covers more than one pharmaceutical substance with regulatory approval?
Bayer Pharma Aktiengesellschaft  APO
Extending the 12-month grace period for filing patent applications – what you need to know
Can the 12-month grace period for filing your patent application be extended? Yes, it can – but subject to the facts.
Ben Dziekan wins IPTA’s prestigious Edward Waters Prize for 2021
Melbourne-based patent attorney Ben Dziekan has been named co-winner of the Institute of Patent and Trade Mark Attorneys of Australia’s prestigious Edwards Waters Prize for 2021.
Your Australian patent application has been opposed – what next?
Australia’s pre‑grant opposition proceedings are playing a more significant role in the strategies of patentees and challengers. So what should a patent owner do when faced with an opposition in Australia?
Why are embryonic stem cells not able to be patented in Australia?
Despite not being specifically excluded under s18 of the Australian Patents Act, technology utilising embryonic stem cells is not able to be patented in Australia. Why is this so?
Recent progress in psychedelic therapies
With increasing awareness of the prevalence of mental ill-health in society, we analyse promising psychedelic therapies that have not yet entered mainstream.
Spotlight Series: Regenerative Medicine – Part 1
The first in a five-part series on one of the most exciting frontiers of scientific research and innovation, regenerative medicine.
Innovation patents: options for challenging problematic cases
What are your options if you identify an innovation patent that affects your freedom to operate?
Patent drafting conventions fall foul of Australian Courts
In a recent opposition appeal decision of the Federal Court of Australia, an Australian patent application by Nalco Company was found invalid for lack of support and lack of clear enough and complete enough disclosure.
Revisiting how early is earliest? Further developments in Australian patent term extension law
Merck Sharp & Dohme Corp. v Sandoz Pty Ltd  FCA 947
Expert evidence keeps RAFT buoyant in strawman patent opposition
Commonwealth Scientific and Industrial Research Organisation (CSIRO) v Cytec Industries Inc.  APO 27
A comeback for Australian patent oppositions
With Australia’s innovation patent system set to end later this month, pre-grant opposition proceedings will likely play a significant role in the strategies of challengers.
Draft roadmap for Australian regenerative medicine released for comment
AusBiotech has released a draft strategic roadmap for a new regenerative medicine Catalyst.
Guidance on patenting diagnostics in Australia: Ariosa Diagnostics v Sequenom
Federal Court confirms that a non-invasive diagnostic test for prenatal conditions is patentable subject matter in Australia.
How the proposed patent box scheme could benefit Australian industry
Principal Karen Sinclair discusses the Australian Government’s proposed patent box scheme and what needs to be considered to ensure successful implementation.
Griffith Hack maintains top tier status in IP STARS 2021 rankings
Griffith Hack has maintained its status as an industry leader in patent prosecution, receiving tier one status in the IP Stars 2021 rankings. Principals Janelle Borham and Amanda Stark were both recognised individually as Patent Stars.
How early is earliest? Developments in Australian patent term extension law
Malcolm Lyons looks at the decision in Ono Pharmaceutical Co, Ltd v Commissioner of Patents which has provided long needed clarity on requests for patent term extension.
The end is near for Australia’s innovation patent system: What you need to know
Australia’s innovation patent system is ending soon, but, there’s still time to take advantage of the system – you just need to act soon.
Australia’s Federal Budget 2021: Key takeaways and opportunities
Investment in tech, research and innovation highlights value of IP protection
Australian government rediscovers R&D value amid COVID-19 crisis
Prior to COVID-19, Australia enjoyed an enviable economic record; outperforming much of the world and avoiding recession for 29 years.
Australian government rediscovers R&D value amid COVID-19 crisis
With two quarters of consecutive GDP contraction due to coronavirus-related shutdowns, Australia is now poised to face economic challenges not experienced since 1991.
Thirteen – unlucky for some: Support and sufficiency in Australia following MSD v Wyeth
The MSD v Wyeth judgment demonstrates the more exacting standard now required for the level of disclosure in patent specifications. It also cements the shift in Australia towards alignment with UK and European requirements.
Ono: Broader is not always better
Why is patent term extension is so important to companies developing and commercialising new pharmaceutical substances?
Protecting your digital health
Track and trace smartphone applications used in the fight against COVID 19 are representative of a relatively new industry falling between the healthcare, IT, medical devices and pharmaceutical sector.
Owning COVID-19: Would if you could?
f the Earth’s biome, viruses are part of its biodiversity, but has consideration been given as to whether anyone can ‘own’ or should benefit from COVID-19?
Griffith Hack announces the elevation of two team members to principal
Griffith Hack is thrilled to formally announce the elevation of Gavin Adkins and Robyn Heard to principal.
Simple steps to better IP portfolio management
Continuous portfolio management is a crucial plank of best practice intellectual asset management.
CRISPR-Cas9 Update: Collision of Trends in IP and Life Sciences
CRISPR-Cas9 genome editing may not just be the greatest scientific breakthrough of this century, but also provides many lessons on patenting life science technologies.